Prosight Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Prosight Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-398,700	Closed	-$2.46M	–	48
2024 Q2	$2.46M	Sell	398,700 -1,001,300	-72%	-$5.53M	0.74%	28
2024 Q1	$7.11M	Sell	1,400,000 -832,242	-37%	-$4.68M	1.98%	16
2023 Q4	$13.4M	Sell	2,232,242 -175,893	-7%	-$1.02M	5.37%	7
2023 Q3	$17M	Sell	2,408,135 -91,865	-4%	-$660K	5.4%	6
2023 Q2	$17.6M	Buy	2,500,000 +1,425,407	+133%	+$11.4M	5.15%	5
2023 Q1	$8.96M	Buy	1,074,593 +957,861	+821%	+$9.22M	4.25%	7
2022 Q4	$1.34M	Buy	116,732 +2,932	+3%	+$36.6K	0.73%	29
2022 Q3	$1.43M	Sell	113,800 -62,880	-36%	-$809K	0.77%	28
2022 Q2	$1.87M	Buy	+176,680	New	+$1.82M	1.47%	18

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Prosight Management's BCRX Position: Q3 2024 in Review

Prosight Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 398,700 shares — an estimated $2.46M sold.

Prosight Management first reported a position in BCRX in Q2 2022 and held it in 9 quarters. The position peaked at $17.6M in Q2 2023. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

Prosight Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Prosight Management sold 398,700 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $2.46M.
Prosight Management first reported a position in BioCryst Pharmaceuticals in Q2 2022 and held it in 9 quarters.
Prosight Management's BioCryst Pharmaceuticals position peaked at $17.6M in Q2 2023.
257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on Prosight Management's 13F filing for Q3 2024, filed 14 Nov 2024.